Logo

Daniel Sikkema

Jul 19, 2017

Quanterix has appointed Daniel Sikkema as vice president of acclerator services for the company's new Simoa Accelerator Lab, a dedicated environment for biomarker research, custom assay development, and clinical sample testing. Sikkema will work to expand the reach of Quanterix's Accelerator Lab services in neurology, oncology, immuno-oncology, infectious disease, inflammatory diseases, and other therapeutic areas. He has previously worked at Frontage Lab, Bristol-Myers Squibb, Wyeth, Merck, Sanofi Pasteur, and GlaxoSmithKline.

Breaking News
The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.